Literature DB >> 9711977

Classification of fluctuations in patients with Parkinson's disease.

N P Quinn1.   

Abstract

Patients with Parkinson's disease (PD) are subject to a wide range of fluctuations in their clinical state, most of them treatment-related but some more disease-related. Short-duration motor fluctuations include freezing and paradoxic kinesis, lasting seconds to minutes. It is important to distinguish between "off" period freezing, which may be helped by measures to increase time "on," and freezing that is present in both "on" and "off" periods, which is difficult if not impossible to treat. Medium-duration fluctuations associated with chronic L-dopa treatment include wearing-off and "on-off" responses, which can involve (a) return of parkinsonism, (b) dyskinesias, and (c) non-motor fluctuations. A poorly understood long-duration pharmacodynamic response to L-dopa lasting up to 2 weeks may also be seen. This may manifest as late deterioration after L-dopa is withdrawn. More importantly, and more commonly, it is important to recognize that the ultimate effect of an alteration in L-dopa treatment may take 2 weeks to equilibrate in the brain. "Optimization" of L-dopa therapy is therefore not a realistic expectation during an inpatient admission and is instead primarily a long-term outpatient procedure. The "off" state is not the same as untreated PD, and may represent rebound worsening after the beneficial effect of L-dopa has worn off. Sometimes there is also transient worsening at the onset of effect of a dose. "Off' period dyskinesias tend to be relatively fixed, painful, and dystonic. Biphasic (beginning and/or end of dose) dyskinesias are often severe, ballistic, and stereotypic. Peak dose or "square wave" dyskinesias comprise a mix of mobile dystonia or chorea that is usually painless. Many patients experience any combination of panic, anxiety, and depression in their "off" periods, and many also experience pain, with instant relief as they turn "on." Other parameters that may vary between the "on" and "off" states include urinary and bowel dysfunction, blood pressure, respiratory function, and sweating attacks. Most but not all of these phenomena can be related to a simplistic but nevertheless usually practically useful model of differing levels of central dopaminergic stimulation. In difficult cases, an acute apomorphine challenge analogous to the effects of a "Tensilon test" in myasthenia gravis may help to determine whether a given clinical feature represents over- or understimulation of central dopamine receptors.

Entities:  

Mesh:

Year:  1998        PMID: 9711977     DOI: 10.1212/wnl.51.2_suppl_2.s25

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

3.  End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Authors:  Astrid Thomas; Laura Bonanni; Angelo Di Iorio; Sara Varanese; Francesca Anzellotti; Anna D'Andreagiovanni; Fabrizio Stocchi; Marco Onofrj
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 4.  Management of pain in Parkinson's disease.

Authors:  Munazza Sophie; Blair Ford
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 5.  The striatal cholinergic system in L-dopa-induced dyskinesias.

Authors:  X A Perez; T Bordia; M Quik
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

6.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Y Du; Z Ma; S Lin; R C Dodel; F Gao; K R Bales; L C Triarhou; E Chernet; K W Perry; D L Nelson; S Luecke; L A Phebus; F P Bymaster; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

Review 7.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

Review 8.  Psychiatric symptoms in Parkinson's disease.

Authors:  Karen E Anderson; William J Weiner
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

9.  Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture.

Authors:  Fanny Schmidt; Pierre Champy; Blandine Séon-Méniel; Xavier Franck; Rita Raisman-Vozari; Bruno Figadère
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

10.  Chronic subthalamic deep brain stimulation improves pain in Parkinson disease.

Authors:  Han-Joon Kim; Sun Ha Paek; Ji-Young Kim; Jee-Young Lee; Yong Hoon Lim; Mi-Ryoung Kim; Dong Gyu Kim; Beom S Jeon
Journal:  J Neurol       Date:  2009-01-22       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.